GlassScriptPhysician profile
Jacob Dwayne Labatut
NPI 1003555624
$3,498.20
in general payments reported to CMS, 2019-2025
44 companies · $747 in 2025
The $747 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $570 · 2023: $1,246 · 2024: $935 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,828 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,828.37 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $315.81 | 2022-2025 | Tremfya, Tecvayli, Darzalex |
| Incyte Corporation | $302.16 | 2022-2023 | Jakafi |
| Abbvie INC. | $296.71 | 2024-2025 | |
| Lilly USA, LLC | $205.09 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Ipsen Biopharmaceuticals, INC | $162.72 | 2023-2025 | Onivyde, Somatuline Depot, Iqirvo |
| Genzyme Corporation | $162.72 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $156.78 | 2022-2025 | Entyvio, Ninlaro, Eohilia |
| Alexion Pharmaceuticals, INC. | $124.05 | 2022-2023 | Ultomiris |
| Pfizer INC. | $121.08 | 2022-2025 | |
| Madrigal Pharmaceuticals | $120.97 | 2024-2025 | Rezdiffra, Resmetirom |
| Beigene USA, INC. | $116.06 | 2022-2024 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $112.34 | 2023-2025 | Dupixent, Libtayo |
| Daiichi Sankyo INC. | $103.66 | 2023-2024 | Enhertu |
| Merck Sharp & Dohme LLC | $94.08 | 2023-2024 | Keytruda, Welireg, Lynparza |
| Ardelyx, INC. | $85.80 | 2024-2025 | Ibsrela |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Labatut listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.